Bexsero (meningococcal group B vaccine) / GSK - LARVOL DELTA

Innovations, challenges, and gaps in the development of an effective vaccine against Neisseria gonorrhoeae, a narrative review. (PubMed, Mol Immunol) - "Clinical trials evaluating the cross-protective effects (approximately 31-46 %) of 4CMenB vaccine against N. gonorrhoeae have been explored, along with recent advances such as recombinant proteins, multivalent and epitope-based approaches, and emerging mRNA platforms...Despite these innovations, translating theoretical approaches into safe, immunogenic, and broadly protective vaccines remains a major challenge. This review underscores the urgent need for continued interdisciplinary research to close existing gaps and develop a feasible efficient vaccine to combat drug-resistant gonorrhea."

Journal • Review • Developmental Disorders • Infectious Disease

MENB-PARD: Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases (clinicaltrials.gov) - P4 | N=263 | Not yet recruiting | Sponsor: University of Sao Paulo General Hospital

New P4 trial • Hematological Disorders • Immunology • Infectious Disease • Meningococcal Infections • Pediatrics • Rheumatology

A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) (clinicaltrials.gov) - P3 | N=226 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Infectious Disease • Meningococcal Infections

Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B expressing a rare porA genosubtype (19-54, 15), Spain, March to April 2024. (PubMed, Euro Surveill) - "According to the national meningococcal disease surveillance protocol, an active search for close contacts of the cases was conducted by public health authorities and timely chemoprophylaxis and/or vaccination with 4CMenB vaccine was recommended to over 200 contacts. The evolution of meningococcal strains with genosubtype 19-54 should be closely monitored, as it might confer a greater transmission capacity."

Journal • Infectious Disease • Meningococcal Infections

Safety Profile of the 4CMenB (Bexsero®) Vaccine: A Systematic Review and Meta-Analysis of Adverse Events in Clinical Trials. (PubMed, Vaccines (Basel)) - "The 4CMenB (Bexsero) vaccine exhibits a favorable safety profile, characterized by a predominance of mild and transient local adverse events. Although several systemic events were reported, their overall frequency was generally low. These findings support the continued inclusion of Bexsero® in routine childhood immunization programs."

Adverse events • Journal • Retrospective data • Review • Dermatology • Fatigue • Meningococcal Infections • Pain

The Impact of 4CMenB Vaccination and Doxycycline post-exposure prophylaxis on Pharyngeal Meningococcal Carriage among MSM using HIV PrEP (EACS 2025) - "No significant changes between the groups were observed in the genetic structure of meningococcal isolates nor in the proportions of resistance to antibiotics (beta lactams, ciprofloxacin, rifampicin, azithromycin or cyclins). Conclusions : The 4CMenB vaccine, contrary to DoxyPEP did not reduce pharyngeal carriage of N. meningitidis among MSM receiving PrEP. Monitoring N. meningitidis AMR in people using doxyPEP is recommended."

Human Immunodeficiency Virus • Infectious Disease • Meningococcal Infections

The relationship between socio-economic inequity indicators and 4CMenB vaccination rates in infants and adolescents in Spain: An ecological correlation study. (PubMed, Hum Vaccin Immunother) - "There were also significant correlations between adolescent vaccination rates and income per capita (r = 0.55; p ≤ .01), higher education rate (r = 0.5; p ≤ .01) and unemployment (r = -0.47; p ≤ .01). These data suggest that lower socio-economic status may influence 4CMenB vaccination rates in Spain, and inclusion of 4CMenB vaccination into Spain's NIP for other age groups could reduce inequity in 4CMenB coverage."

Journal • Infectious Disease • Meningococcal Infections

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (clinicaltrials.gov) - P1/2 | N=576 | Terminated | Sponsor: Sanofi Pasteur, a Sanofi Company | Phase classification: P1 ➔ P1/2

Phase classification • Infectious Disease • Meningococcal Infections

Effectiveness of the four-component protein-based meningococcal vaccine against Neisseria gonorrhoeae infections: Mounting evidence and public health implications for Canada. (PubMed, Can Commun Dis Rep) - "Review of published studies and on-going trials with the four-component meningococcal serogroup B vaccine (4CMenB-Bexsero®)...Recommendations on the use of 4CMenB for individuals at high risk of gonorrhea infection have been issued in the United Kingdom and New York state based on results of observational studies. If results of observational studies are confirmed by randomized trials with an acceptable cost-effectiveness profile in the Canadian context, a targeted immunization program using 4CMenB could be implemented."

Clinical • Journal • Infectious Disease • Meningococcal Infections

Real-World Vaccine Effectiveness and Impact of the 4CMenB Vaccine in Infants, Children, and Adolescents: A Systematic Literature Review (IDWeek 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Review • Infectious Disease

Real-World 4CMenB Vaccine Duration of Protection in Infants and Children (IDWeek 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Antibody Persistence of the 4CMenB Vaccine in Infants: A Systematic Literature Review (IDWeek 2025) - No abstract available

Review • Infectious Disease

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (clinicaltrials.gov) - P1/2 | N=1215 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Meningococcal Infections

The 2025 UK 4CMenB vaccine programme for GBMSM at high risk of gonorrhoea. (PubMed, Sex Transm Infect) - No abstract available

Journal • Infectious Disease

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006). (PubMed, Vaccine) - "A two-dose regimen of ChAdOx1 nCoV-19 was immunogenic and safe in the trial population. No vaccine-related serious adverse events were reported. Immune responses persisted to 12 months in participants who did not experience breakthrough infection, This trial was registered with ISRCTN, trial number 15638344."

Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases

VIRGo – Vaccine-induced Immune Responses against Gonorrhoea: A study to investigate immune response induced by the 4CMenB vaccine against gonorrhoea (ANZCTR) - P2/3 | N=60 | Recruiting | Sponsor: Gold Coast University Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

BIYELA - Bexsero Immunisation in Young Women in Africa (clinicaltrials.gov) - P3 | N=1100 | Active, not recruiting | Sponsor: University of Washington | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Meningococcal Infections

Direct whole-genome sequencing enables strain typing of unculturable Neisseria meningitidis from oropharyngeal carriage specimens. (PubMed, Microb Genom) - P=N/A, P4 | "Sequences were analysed using currently available bioinformatic tools, including the characterization of genogroup, multi-locus sequence typing (MLST), Bexsero Antigen Sequence Typing (BAST), porA and fetA type.Sensitivity of dWGS typing compared to WGS for genogroup, MLST, porA, fetA and BAST schemes was 88.89%, 72.22%, 100%, 94.44% and 88.24%, respectively...An alternative phylogenetic method (phylotyping) correctly predicted the clonal complex for 93.46% of the samples assessed. These results demonstrate that dWGS enables high-resolution molecular fine typing and can be applied to unculturable samples in N.m. carriage studies."

Journal • Infectious Disease • Meningococcal Infections

A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) (clinicaltrials.gov) - P3 | N=312 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Infectious Disease • Meningococcal Infections

Long-term protection against invasive meningococcal B disease and gonococcal infection five years after implementation of funded childhood and adolescent 4CMenB vaccination program in South Australia: an observational cohort and case-control study. (PubMed, Clin Infect Dis) - "4CMenB demonstrates high protection against MenB disease in children and adolescents at 5 years. Moderate protection against the first and subsequent gonococcal infections in adolescents was observed up to 5 years post vaccination with waning evident after 5 years."

Journal • Observational data • Infectious Disease • Meningococcal Infections

[[Translated article]]New Prevention Measures in Venereology: Evidence Review on the DoxiPrEP/PEP Antibiotic and the 4CMenB Vaccine. (PubMed, Actas Dermosifiliogr) - "The most interesting one, based on the evidence obtained, is the use of doxycycline and meningococcal B vaccines. Specialists in dermatology and venereology must be informed about these new developments that may have an impact on the way in which STIs are managed worldwide. This is a scientific evidence review of these new interesting primary and secondary prevention strategies to control STIs in a high-risk population."

Journal • Review • Dermatology • Infectious Disease • Meningococcal Infections

ENHANCING CARE FOR SICKLE CELL PATIENTS WITH A REAL-TIME LONGITUDINAL PATIENT TRACKING FACILITY WITHIN AN ELECTRONIC PATIENT RECORD SYSTEM (EHA 2025) - "Of 156 patients, 25 left our care between June 2021 and December 2024, resulting in two cohorts of n1=81 and n2=131.Quality indicators were selected based on the Standards for Clinical Care of Adults with SCD in the UK (Sickle Cell Society, 2018).Data collection included hydroxyurea (HU) usage, and urine testing for albumin creatinine clearance (ACR) at each time point. Vaccination records were obtained from primary care for 129 patients (67 (2021) and 114 (2024)).Completeness of vaccination uptake was measured through uptake of influenza (annual), the bexsero (any time) and the pneumovax (within 5 years) of the two timepoints.To assess hospital workload over this period, we recorded cumulative A&E attendances, haematology day unit attendance, clinic appointments, number of nights in hospital and admissions from A&E.A&E attendances rose from 34 (2021) to 62(2024), HDU attendance from 10 (2021) to 81 (2024), number of nights in hospital from 170 (2021) to 355..."

Clinical • Genetic Disorders • Hematological Disorders • Infectious Disease • Influenza • Respiratory Diseases • Sickle Cell Disease

Genomic surveillance of invasive Neisseria meningitidis isolates circulating in Paraguay, 2009-2021. (PubMed, Int Microbiol) - "This is the first genomic study of Neisseria meningitidis conducted in Paraguay, enabling a novel understanding of the genetic characteristics of invasive isolates. The generation of genomic data is essential for monitoring the spread of circulating lineages or clones that may alter their antigenic profiles to evade host immune responses."

Journal • CNS Disorders • Infectious Disease • Meningococcal Infections

A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) (clinicaltrials.gov) - P3 | N=312 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • CNS Disorders • Infectious Disease • Meningococcal Infections

INVASIVE MENINGOCOCCAL DISEASE TREND IN PEDIATRIC POPULATION OF CHILE AFTER THE INTRODUCTION OF 4CMENB VACCINE FOR INFANTS (ESPID 2025) - "The impact of MCV-ACWY and 4CMenB has been significant in terms of the reduction in targeted population. Nevertheless, in order to make progress in the IMD control, it is essential that MCV-ACWY is included in adolescents, to achievie an indirect effect in other age-groups"

Clinical • Infectious Disease • Meningococcal Infections